Hybrid aav-anellovectors
AssigneeFlagship Pioneering Innovations V, Inc.
InventorsSimon Delagrave, Kevin James Lebo, Michael James DiBiasio-White, Dhananjay Maniklal Nawandar
Life of this patent
Estimating the term…
Abstract
This invention relates generally to compositions for making and administering anellovectors and uses thereof.
Claims7
A viral particle comprising a circular DNA comprising (i) an AAV origin of replication, (ii) a promoter operably linked to a sequence encoding a therapeutic RNA or polypeptide, and (iii) a sequence that binds an Anellovirus ORF1 molecule, the circular DNA being encapsidated by a capsid comprising an Anellovirus ORF1 molecule.
A vector comprising:
- a) a proteinaceous exterior comprising an Anellovirus ORF1 molecule;
- and
- b) a genetic element comprising a non-Anellovirus origin of replication;
- optionally wherein the genetic element further comprises:
- (i) a nucleic acid sequence encoding an exogenous effector, and/or (ii) a promoter element operatively linked to the nucleic acid sequence encoding the exogenous effector.
A genetic element comprising:
- a protein binding sequence that specifically binds an Anellovirus ORF1 molecule (e.g., a 5′ UTR);
- and
- an AAV origin of replication, e.g., comprised in a first AAV inverted terminal repeat (ITR);
- optionally, a nucleic acid sequence encoding an exogenous effector (e.g., a therapeutic exogenous effector);
- and
- optionally, a promoter element operatively linked to the nucleic acid sequence encoding the exogenous effector.
A system comprising:
- a) a first nucleic acid, wherein the first nucleic acid is a genetic element or a genetic element construct, the first nucleic acid comprising:
- an AAV origin of replication, e.g., comprised in a first AAV inverted terminal repeat (ITR);
- optionally, a nucleic acid sequence encoding an exogenous effector (e.g., a therapeutic exogenous effector);
- and
- optionally, a promoter element operatively linked to the nucleic acid sequence encoding the exogenous effector;
- b) a second nucleic acid encoding an Anellovirus ORF1 molecule.
A method of making a therapeutic composition, comprising:
- (a) providing one or a plurality of host cells comprising exogenous DNA comprising
- (i) an AAV origin of replication,
- (ii) a promoter operably linked to a sequence encoding a therapeutic effector (e.g., a therapeutic RNA or polypeptide),
- (iii) a sequence encoding an Anellovirus ORF1 molecule,
- (iv) optionally a sequence encoding an Anellovirus ORF2 molecule,
- (v) optionally a sequence encoding an AAV REP2 sequence
- (vi) optionally a sequence encoding one or a plurality of helper proteins, e.g., an Adenovirus helper protein, e.g., an E2A molecule, an Adenovirus E4 molecule, and/or an Adenovirus VARNA molecule;
- (b) culturing the one or plurality of host cells under conditions suitable for formation of vectors (e.g., anellovectors, e.g., viral particles) comprising a proteinaceous exterior (e.g., capsid) comprising a sufficient number of the ORF1 molecules to enclose (e.g., encapsidate) the genetic element;
- (c) purifying the vectors produced in step (b) from the cell culture,
- thereby making a therapeutic composition.
Dependencies are inferred from the claim text.